SLC12A5 and epilepsy: Similarly, SLC12A5 mutations [13], affecting K-Cl cotransporter (KCC2) function, suggest a potential role for therapies aimed at restoring chloride homeostasis in neurons, such as bumetanide, which is under investigation for epilepsy management.